Crestwood Advisors Group LLC Sells 1,043 Shares of AstraZeneca PLC (NASDAQ:AZN)

Crestwood Advisors Group LLC decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 17.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,916 shares of the company’s stock after selling 1,043 shares during the quarter. Crestwood Advisors Group LLC’s holdings in AstraZeneca were worth $383,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. increased its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new position in AstraZeneca during the 2nd quarter worth $26,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca during the first quarter worth $29,000. Hobbs Group Advisors LLC bought a new stake in shares of AstraZeneca in the second quarter valued at about $35,000. Finally, Versant Capital Management Inc grew its stake in shares of AstraZeneca by 1,614.8% in the second quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock valued at $36,000 after acquiring an additional 436 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on AZN shares. TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Down 3.7 %

Shares of AZN opened at $63.85 on Thursday. The firm has a 50 day simple moving average of $78.45 and a two-hundred day simple moving average of $78.75. The company has a market cap of $197.97 billion, a P/E ratio of 30.85, a P/E/G ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.